Alnylam Pharmaceuticals announced new findings from several clinical trials that continue to demonstrate the effectiveness of givosiran, the…
Articles by Joana Carvalho, PhD
Glycyrrhizin may be an effective treatment option for patients who develop porphyria cutanea tarda associated with alcohol abuse, a…
People with porphyria cutanea tarda (PCT) have higher risks of developing gastrointestinal diseases and certain types of cancer,…
Continued support, counseling, and education are important for patients with acute intermittent porphyria so that they can use that…
Non-invasive bioenergetic tests may be useful biomarkers to assess disease activity in patients with different types of porphyria, a…
Alnylam Pharmaceuticals has completed its submission of a new drug application (NDA) to the U.S. Food and…
Patients with porphyria cutanea tarda have higher risks of developing liver and other types of cancer and of dying…
Prophylactic (preventive) treatment with heme reduces the frequency of acute attacks, improving the quality of life and reducing healthcare costs…
A Phase 3 clinical trial evaluating the effects of givosiran, an investigational therapy for acute hepatic porphyria (AHP), has completed…